Kumar Dhanasekharan
Chief Tech/Sci/R&D Officer chez RENOVACOR, INC.
Profil
Kumar Dhanasekharan is currently the Senior Vice President-Technical Operations at Renovacor, Inc. Previously, he worked as the Vice President-Technical Operations at SwanBio Therapeutics, Inc. He completed his undergraduate degree at the Indian Institute of Technology Madras and his doctorate at Rutgers University, Camden.
Postes actifs de Kumar Dhanasekharan
| Sociétés | Poste | Début |
|---|---|---|
| RENOVACOR, INC. | Chief Tech/Sci/R&D Officer | 04/10/2021 |
Anciens postes connus de Kumar Dhanasekharan
| Sociétés | Poste | Fin |
|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Corporate Officer/Principal | - |
Formation de Kumar Dhanasekharan
| Indian Institute of Technology Madras | Undergraduate Degree |
| Rutgers University, Camden | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
